Features of Childhood Acute Myeloid Leukemia in Iran: a Report from Double Center Study

Azim Mehrvar1, Mohammad Saeid Rahiminejad2, Amir Abbas Hedayati Asl3

  • 1Department of Pediatric Hematology Oncology, MAHAK s' Pediatric Cancer Treatment and Research Center, Army University of Medical Science, Tehran, Iran.

Acta Medica Iranica
|January 11, 2016
PubMed

Insights

This study on childhood Acute Myeloblastic Leukemia (AML) found common features and molecular abnormalities. Survival rates were lower compared to developing countries, highlighting a need for improved interventions.

Area of Science:

  • Pediatric Oncology
  • Hematologic Malignancies
  • Childhood Cancers

Background:

  • Acute Myeloblastic Leukemia (AML) is a significant childhood malignancy.
  • Understanding common features is crucial for improving pediatric AML prognosis.
  • Limited data exists on epidemiological characteristics and survival outcomes in specific pediatric populations.

Purpose of the Study:

  • To evaluate common epidemiological features of childhood Acute Myeloblastic Leukemia.
  • To identify prevalent subtypes and molecular abnormalities in pediatric AML patients.
  • To assess survival rates and relapse patterns in children diagnosed with AML.

Main Methods:

  • Retrospective analysis of 104 pediatric patients (<15 years) diagnosed with AML between 2007-2011.
  • Data collection included basic epidemiological information.
  • Statistical analysis performed using SPSS version 22.

Main Results:

  • The study included 54.8% males with a male/female ratio of 1.2 and a mean age of 6.5 years.
  • Common subtypes were M3, M4, non-M3, and M2; frequent molecular abnormalities included t(15;17) and inv(16).
  • A 3-year overall survival rate of 42% was observed, with 19.2% experiencing early relapse.

Conclusions:

  • Childhood AML shares frequency with developing countries but exhibits lower survival rates.
  • Findings underscore the need for enhanced preventive strategies, resource allocation, and updated treatment modalities.
  • Data can inform public health policies and support programs for pediatric AML patients and families.